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ABSTRACT
Nonviral delivery vectors are attractive for gene therapy approaches in tissue engineering, but suffer from
low transfection efficiency and short-term gene expression. We hypothesized that the sustained delivery of
poly(ethylenimine) (PEI)-condensed DNA from three-dimensional biodegradable scaffolds that encourage cell
infiltration could greatly enhance gene expression. To test this hypothesis, a PEI-condensed plasmid encod-
ing -galactosidase was incorporated into porous poly(lactide-co-glycolide) (PLG) scaffolds, using a gas foam-
ing process. Four conditions were examined: condensed DNA and uncondensed DNA encapsulated into PLG
scaffolds, blank scaffolds, and bolus delivery of condensed DNA in combination with implantation of PLG
scaffolds. Implantation of scaffolds incorporating condensed -galactosidase plasmid into the subcutaneous
tissue of rats resulted in a high level of gene expression for the entire 15-week duration of the experiment, as
exemplified by extensive positive staining for -galactosidase gene expression observed on the exterior sur-
face and throughout the cross-sections of the explanted scaffolds. No positive staining could be observed for
the control conditions either on the exterior surface or in the cross-section at 8- and 15-week time points. In
addition, a high percentage (55–60%) of cells within scaffolds incorporating condensed DNA at 15 weeks dem-
onstrated expression of the DNA, confirming the sustained uptake and expression of the encapsulated plas-
mid DNA. Quantitative analysis of -galactosidase gene expression revealed that expression levels in scaffolds
incorporating condensed DNA were one order of magnitude higher than those of other conditions at the 2-
week time point and nearly two orders of magnitude higher than those of the control conditions at the 8- and
15-week time points. This study demonstrated that the sustained delivery of PEI–condensed plasmid DNA
from PLG scaffolds led to an in vivo long-term and high level of gene expression, and this system may find
application in areas such as bone tissue engineering.
609
OVERVIEW SUMMARY
Gene therapy approaches to tissue engineering using non-
viral vectors have great potential, but low transfection effi-
ciency and short-term gene expression limit practical ap-
plications. We propose that increased transfection can be
achieved through local and sustained delivery of condensed
plasmid DNA from three-dimensional biodegradable poly-
mer scaffolds that promote cell infiltration. To test this, PEI-
condensed and uncondensed -galactosidase plasmid was
either incorporated into poly(lactide-co-glycolide) scaffolds
and implanted into the subcutaneous tissue of rats, or in-
jected into the site at the time of implantation (bolus deliv-
ery). Sustained delivery of condensed DNA led to extensive
gene transfer, and an approximately two orders of magni-
tude increase in -galactosidase expression, as compared
with the other conditions. Further, whereas bolus delivery
led to transient expression, sustained delivery maintained a
high expression level for the 15-week duration of the ex-
periment. These results indicate that combining DNA con-
densation with sustained delivery from a polymer can allow
long-term and efficient gene transfer in vivo.
1Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109.
2Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109.
3College of Pharmacy, University of Iowa, Iowa City, IA 52242.
4Division of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
INTRODUCTION
GENE THERAPY APPROACHES to tissue engineering have beeninvestigated using a variety of systems, including the de-
livery of genetically modified cells, injection of viral mi-
croparticles, and delivery of plasmid-based systems (Murphy
and Mooney, 1999; Shea et al., 1999; Bonadio, 2000; Cohen
et al., 2000; Hidaka et al., 2002; Lee et al., 2002; Huard et al.,
2003; Wu et al., 2003). Viral gene delivery systems rely on ge-
netically engineered viruses to deliver the gene to the target
cells (Ledley et al., 1987; Hafenrichter et al., 1994a,b; Kay et
al., 1995, 1997; Barry et al., 1996; Kessler et al., 1996; Nabel,
1999). Nonviral gene delivery systems use plasmid DNA that
can be formulated with a variety of carrier molecules (Zhou et
al., 1991; Boussif et al., 1996; Fominaya and Wels, 1996; Lee
and Huang, 1996; Alila et al., 1997; Hara et al., 1997; Jong et
al., 1997; Kircheis et al., 1997; Kim et al., 1998). Viral vec-
tors generally display high efficiency. However, their appli-
cation has been hampered by a variety of issues, including a
limitation on the size of inserted DNA for certain viruses, un-
controllable expression of inserted genes, high immunogenic-
ity that could result in patient death, and the potential for the
insertion of the new gene into the host cell genome in a man-
ner that leads to mutagenesis (Bonadio et al., 1998). Delivery
of plasmid DNA has been pursued as an alternative approach
to circumvent these issues. Plasmid DNA is economical and
relatively simple to manufacture, and has a chemistry that lends
itself to polymer-based drug delivery systems. Furthermore,
plasmid DNA has limited safety issues associated with toxicity
and immunogenicity (Winn et al., 2000). In addition, issues as-
sociated with direct protein delivery, such as instability and lack
of posttranslational modification of recombinantly produced
proteins, are circumvented as plasmid DNA is inherently sta-
ble and transfected cells possess the biosynthetic capability for
functional protein production (Yin et al., 1995; Fang et al.,
1996). Complexes between the therapeutic DNA and nonviral
delivery systems are easy to construct and theoretically there is
no limit as to the size of the gene that can be used with this ap-
proach (Weidner, 2002; Wolff and Herweijer, 2003). The plas-
mid DNA can be designed to encode the gene of interest, as
well as the promoter and enhancer elements needed to achieve
appropriate gene expression. However, the low transfection ef-
ficiency of plasmid DNA has been a major limitation in gene
delivery applications.
One element of many tissue-engineering applications is the
fabrication of a biocompatible three-dimensional scaffold mate-
rial to replace the structural and functional characteristics of
damaged tissues. Synthetic materials are an attractive choice for
scaffold fabrication because of their reproducibility, and ability
to be produced on a large scale. In addition, their mechanical
properties and degradation rates can be readily manipulated so
that they can be designed for specific applications (Kim and
Mooney, 1998a). In this approach, the polymer scaffolds define
the space for tissue development, serve as the delivery vehicle
for growth factors to specific anatomic sites, and can also be
used for simultaneous cell transplantation (Chaignaud et al.,
1997; Wong and Mooney, 1997; Murphy and Mooney, 1999).
Poly(lactic-co-glycolic acid) (PLGA) is one class of synthetic
material that is often used because of its ability to be customized
to meet a particular absorption time requirement, and PLGA has
a history of clinical use in various applications (Burg et al.,
2000). In addition, investigators have effectively used PLGA for
tissue-engineering purposes and demonstrated compatibility in
vitro and in vivo (Kim et al., 1994; Mooney et al., 1997; Haar
et al., 1998; Kim and Mooney, 1998b; Vunjak-Novakovic et al.,
1998; Thomson et al., 1999) in a number of situations, includ-
ing applications involving the localized delivery of plasmid
DNA for in vivo transfection (Shea et al., 1999). The delivery
of plasmid DNA through localized polymeric scaffolds is an at-
tractive approach to direct tissue development in tissue-engi-
neering applications. The major advantage of this approach over
bolus or intravenous injection and virus-based approaches is that
it bypasses the side effects associated with the systemic deliv-
ery of genetic materials and the disadvantages associated with
the common use of viral vectors. Further, polymeric gene de-
livery vehicles have the potential to effectively and safely de-
liver genes to target cells. PLGA scaffolds incorporating plas-
mid DNA allow cell infiltration and uptake of DNA for
subsequent production of proteins involved in tissue formation
(Bonadio et al., 1999; Shea et al., 1999). The application of lo-
calized gene delivery with plasmid DNA in tissue engineering
was originally proposed as a gene-activated matrix (GAM), us-
ing collagen as the polymeric scaffold, and this system has been
applied to bone regeneration (Goldstein and Bonadio, 1998;
Bonadio et al., 1999, 2000). In addition, PLGA scaffolds fabri-
cated by the gas foaming process have been utilized to deliver
plasmid encoding platelet-derived growth factor, and this re-
sulted in increased blood vessel and granulation tissue forma-
tion (Shea et al., 1999). This latter approach enables control over
temporal gene expression as the new tissues form, and unde-
sired activity is presumably lost after the polymeric vehicle is
exhausted of plasmid and tissue formation is complete.
Despite potential advantages of plasmid delivery approaches
in tissue regeneration, plasmid DNA typically demonstrates
low transfection efficiency in vivo. This is a result of its 
chemical, enzymatic, and colloidal instability, macrophage up-
take, and nonspecific targeting (Mahato, 1999). Therefore,
gene therapy success is largely dependent on the development
of vectors that allow efficient delivery to targeted sites at a
high expression level (Li and Huang, 2000). The low trans-
fection efficiency of plasmid DNA in these types of systems
can potentially be overcome by condensing plasmid DNA with
polycationic condensing agents, including poly(ethylenimine)
(PEI) (Boussif et al., 1995; Blessing et al., 2001; Gautam et
al., 2001; Lee et al., 2001; Lemkine and Demeneix, 2001;
O’Neill et al., 2001). The condensing agents form positively
charged small particles that facilitate cellular entry, enhance
the stability of plasmid DNA, and increase transfection effi-
ciency. PEI has been shown to be highly effective as a nonvi-
ral delivery vehicle, without additional endosomal buffering
agents such as chloroquine, both in vitro and in vivo (Boussif
et al., 1995; Boletta et al., 1997; Gautam et al., 2001; Lemkine
and Demeneix, 2001).
We hypothesized that the sustained delivery of plasmid DNA
condensed with PEI from porous PLGA scaffolds would lead
to increased and long-term transfection in vivo. We have pre-
viously developed an approach to encapsulate and deliver PEI-
condensed DNA from three-dimensional biodegradable PLGA
scaffolds fabricated by a gas foaming process (Huang et al.,
2003). The parameters for in vivo transfection utilized in this
study were obtained from the optimized in vitro parameters (200
g of plasmid DNA and a PEI–DNA charge ratio of 7) found
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FIG. 1. Gross macroscopic photographs of (A, E, and I) blank scaffolds, (B, F, and J) scaffolds incorporating plasmid DNA,
(C, G, and K) bolus injection of condensed DNA, and (D, H, and L) scaffolds incorporating condensed DNA. Scaffolds were
retrieved 2 weeks (A–D), 8 weeks (E–H), and 15 weeks (I–L) after subcutaneous implantation and stained for -Gal. At 
2 weeks, the blank scaffolds displayed no positive staining in cross-section (A). Scaffolds encapsulating uncondensed DNA or
the condition utilizing bolus injection of condensed DNA led to light staining in cross-section (B and C). Scaffolds that deliv-
ered condensed DNA demonstrated intensive positive staining in cross-section (D). At 8 and 15 weeks, blank scaffolds (E and
I), scaffolds encapsulating uncondensed DNA (F and J), or the condition utilizing bolus injection of condensed DNA (G and K)
led to no positive staining in cross-section. Scaffolds that delivered condensed DNA demonstrated intensive positive staining in
cross-section (H and L). All photographs were taken at the same magnification, and a size bar is shown in (A–D).
in that study. PEI–DNA condensates were prepared by com-
bining pCMVL plasmid and branched PEI (MW 25 kDa). The
mean particle size of PEI–DNA condensates with optimal up-
take was determined to be in the range of 60–150 nm. Con-
densates encapsulated within PLGA scaffolds, using sucrose as
the porogen, tended to remain entrapped, with an efficiency of
90%, whereas uncondensed plasmid DNA exhibited a high loss
of DNA (20% retention efficiency). The charge ratio strongly
influenced gene expression mediated by PEI-condensed DNA
entrapped in PLGA scaffolds, with maximal gene expression at
a charge ratio of 7 or higher. In addition, gene expression lev-
els increased in proportion to the condensed DNA dose up to
200 g, with no additional increase beyond that dose. There-
fore the optimal PEI–DNA condensate charge ratio of 7 and a
plasmid DNA dose of 200 g were used in this study to eval-
uate in vivo gene expression. We also included a condition in-
volving a one-time bolus injection of condensed DNA to con-
trast the characteristics of long-term delivery in this system.
The applicability of this system to transfect cells in vivo with
DNA condensates was examined by subcutaneous implantation
of the scaffolds into rats.
MATERIALS AND METHODS
Chemicals
Branched PEI (MW 25 kDa) was purchased from Sigma-
Aldrich (St. Louis, MO). Sucrose was purchased from Sigma
(St. Louis, MO). Poly(D,L-lactic-co-glycolic acid) (PLGA)
85:15 was purchased from Alkermes (Cambridge, MA). Plas-
mid DNA (pNGVL, 7.5 kb) encoding the nucleus-targeting 
-galactosidase (nt -Gal) under the control of the cyto-
megalovirus (CMV) promoter was purified from Escherichia
coli, using a Qiagen ultrapure column (Qiagen, Chatsworth,
CA) according to the manufacturer’s instruction. This approach
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FIG. 2. (A) Comparison of mass of scaffolds and (B) comparison of cell number in scaffolds retrieved at 2, 8, and 15 weeks.
Open columns, blank scaffolds; dotted columns, scaffolds incorporating plasmid DNA; hatched columns, scaffolds with bolus
injection of condensed DNA; solid columns, scaffolds incorporating condensed DNA. Experimental values are reported as means
(n  6)  SD. *Statistical significance relative to 2- and 8-week time points within each condition (p  0.05).
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FIG. 3. Photomicrographs of histological sections of samples stained for -galactosidase activity at 15 weeks. Scaffold incor-
porating condensed DNA (A), and scaffold incorporating plasmid DNA (B), stained with eosin only. (C) Section from scaffold
incorporating condensed DNA counterstained with hematoxylin. (D) Higher magnification of (C), showing a greater intensity of
nuclear staining in the transfected cells (arrows). Original magnification: (A–C) 200; (D) 400; scale bars are shown for each
photomicrograph.
typically yielded plasmid DNA that was 50:50 supercoiled:open
circular, as determined by agarose gel electrophoresis. 5-
Bromo-4-chloro-3-indolyl--D-galactopyranoside (X-Gal) and
-galactosidase staining solutions were purchased from Spe-
cialty Media (Phillipsburg, NJ). A -galactosidase quantifica-
tion kit (Galacto-Star) was purchased from Applied Biosystems
(Foster City, CA). Antibodies for fluorescence-activated cell-
sorting (FACS) analysis, including anti-rat CD45–fluorescein
isothiocyanate (FITC) (green) for leukocytes and anti-rat
CD31–phycoerythrin (PE) (red) for endothelial cells, were pur-
chased from BD Biosciences Immunocytometry Systems (San
Jose, CA).
Preparation of PLGA sponges
PEI–DNA condensates were prepared by combining 200 g
of plasmid in 4 ml of HEPES buffer (5 mM, pH 7.4) with 4 ml
of PEI (10 mM). Sucrose (1%, w/v) was added and condensates
were rapidly frozen, using dry ice in ethanol, and lyophilized for
72 hr. Freeze-dried PEI–DNA condensates were combined with
milled sucrose (250–425 m) and 85:15 polylactide:glycolide
copolymer particles (106–250 m). Sponges were prepared at
91:9 weight ratio of porogen:PLGA by combining 728 mg of su-
crose and PEI–DNA condensate with 72 mg of PLGA. Sponges
were fabricated by compression molding 800 mg of the dry mix-
ture at 1500 psi for 1 min, using a 13-mm die set from Pike Tech-
nologies (Madison, WI) and a Carver model “C” hydraulic press
(Pike Technologies). The compressed pellet (2  13 mm) was
then foamed into a scaffold via a gas foaming process (Harris et
al., 1998) in a custom-designed stainless steel high-pressure ves-
sel using dry CO2 gas at 800 psi for 24 hr. A rapid reduction in
pressure causes the polymer particles to expand and fuse into an
interconnected structure. Sucrose was leached from the sponges
by immersion in phosphate-buffered saline (PBS). Sponges con-
taining naked plasmid DNA were also prepared by mixing 200
g of lyophilized plasmid DNA, sucrose, and PLGA followed
by the gas foaming and particulate leaching process.
In vivo transfection studies
The ability of the released plasmid to transfect cells in vivo
was assessed by implantation of PLG sponges containing plas-
mid DNA into the subcutaneous tissue of male Lewis rats
(250–300 g). Experiments were performed by implanting blank
scaffolds, scaffolds encapsulating condensed plasmid DNA,
and scaffolds encapsulating plasmid DNA, and by directly in-
jecting condensed DNA (in Tris–EDTA buffer), into the sub-
cutaneous tissue of rats. Scaffolds encapsulating plasmid DNA
contained 200 g of plasmid DNA per scaffold. Six samples
were used for each condition at each time point. To implant
scaffolds, Lewis rats (Charles River Laboratories, Wilmington,
MA) were anesthetized via intraperitoneal injection of ketamine
(80 mg/kg) and xylazine (10 mg/kg). Midlongitudinal skin in-
cisions approximately 15 mm in length were made on the dor-
sal surface of each rat, using a scalpel blade, and four subcu-
taneous pockets were created per animal via blunt dissection.
One implant of each condition was placed per animal. Incisions
were then closed with black filament nylon sutures (Ethicon,
Somerville, NJ). After 2, 8, and 15 weeks, the animals were
killed by cervical dislocation and the implants were retrieved.
Treatment of experimental animals was in accordance with Uni-
versity of Michigan (Ann Arbor, MI) animal care guidelines,
and all National Institutes of Health (NIH, Bethesda, MD) an-
imal-handling procedures were observed.
Analysis of tissue explant -galactosidase expression
The mass of the scaffolds and the cell numbers within the
scaffolds were determined after retrieval, and scaffolds were
bisected into two equal pieces. One-half of each scaffold was
used for -Gal staining and subsequent histological analysis,
and the other half was flash frozen in liquid nitrogen for quan-
tification of -Gal expression. The scaffolds were stained with
X-Gal to detect -galactosidase production, and the staining
was confirmed by the nucleus-specific staining of the trans-
fected cells. Specifically, samples used for staining were placed
in a fixing solution (37.6% formaldehyde [53.1 ml/liter] and
50% glutaraldehyde [4 ml/liter] in PBS) at 4°C for 90 min.
Samples were subsequently rinsed with rinse solution (EGTA
[1.900 g/liter] and MgCl2  6H2O [0.406 g/liter] in phosphate
buffer) once and then placed in rinse solution for 30 min in
the dark at room temperature. After 20–25 min, the X-Gal sub-
strate and tissue stain base solution [MgCl2  6H2O, 0.406
g/liter; K3Fe(CN)6, 1.645 g/liter; K4Fe(CN)6, 2.110 g/liter; de-
oxycholate, 0.1 g/liter; and Nonidet P-40, 0.2 ml/liter in phos-
phate buffer] were thawed to make the staining solution. Sam-
ples were then placed in the staining solution for 1.5 hr. After
staining, samples were placed in tubes containing 70% etha-
nol, paraffin embedded, and sectioned (Histology Core Facil-
ity, University of Michigan Dental School, Ann Arbor, MI).
The percentage of transfected cells in tissue sections was esti-
mated by counting the fraction of cells positively stained in
eight randomly chosen locations per section. Positively stained
and total cell numbers were determined by comparing slides
stained with eosin only, and slides stained with both eosin and
hematoxylin.
To quantify -galactosidase enzyme activity, samples were
either flash frozen and stored at 20°C for later analysis, or
analyzed immediately. At the time of analysis, samples were
washed twice with ice-cold phosphate-buffered saline (cal-
cium and magnesium free) and then treated with lysis buffer
to lyse the cells. The lysate was centrifuged to pellet cell de-
bris, and the supernatant was added to the reagent provided in
the -galactosidase quantification kit (Galacto-Star). Relative
light units (RLU) were recorded on a luminometer (Lumat LB
9501; Berthold Detection Systems, Pforzheim, Germany) with
10-sec integration. In addition, FACS analysis was performed
to identify cell types infiltrating the scaffolds. Briefly, sam-
ples were cut into small pieces on retrieval and placed in a
collagenase solution and incubated for 45 min at 37°C. After
incubation, cell strainers (pore size, 45 m) were used to re-
move debris remaining in the solution. Released cells were 
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FIG. 4. Quantification of -Gal expres-
sion in samples retrieved at 2, 8, and 15
weeks. Open columns, 2-week time point;
dotted columns, 8-week time point; solid
columns, 15-week time point. Experimen-
tal values are reported as means (n  6) 
SD. *Statistical significance relative to the
2-week time point; **statistical signifi-
cance relative to the blank scaffolds, the
scaffolds incorporating plasmid DNA, and
the condition involving bolus injection of
condensed DNA (p  0.05). Relative light
units (RLU) represent a measurement of
gene expression level via light emission as
determined by luminometer.
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resuspended in cold PBS and counted, followed by the addi-
tion of antibodies for surface antigen recognition, and subse-
quently analyzed (Flow Cytometry Core Facility, University
of Michigan).
RESULTS
The ability of plasmid incorporated within polymers to
transfect cells in vivo was assessed by implanting PLGA scaf-
folds encapsulating a plasmid DNA encoding nucleus-targeted
-galactosidase (-Gal) into the subcutaneous tissue of Lewis
rats. In addition, the following control conditions were exam-
ined: encapsulated uncondensed DNA, blank scaffolds, and bo-
lus delivery of condensed DNA. The latter condition involved
the direct injection of condensed DNA into the scaffold at the
time of surgery, instead of its incorporation for sustained de-
livery. To grossly identify -galactosidase expression, scaf-
folds were stained with X-Gal after being retrieved at each time
point. At 2 weeks, on gross macroscopic examination, blank
scaffolds displayed no positive staining either at the outer sur-
face or in cross-section (Fig. 1A). Scaffolds encapsulating un-
condensed DNA, and the condition involving bolus injection
of condensed DNA, demonstrated only slight positive staining
at the outer surface of the scaffolds, and light staining was 
observed in cross-sections of the scaffolds (Fig. 1B and C).
Bolus injection of condensed DNA appeared to lead to a greater
amount of positive staining than did delivery of uncondensed
DNA. In contrast, scaffolds containing encapsulated condensed
DNA led to positive -galactosidase staining over the outer
surface of the scaffold, and intense staining was present at 
least three-fourths of the distance into the scaffolds (Fig. 1D).
No evidence of positive staining was observed for the blank
scaffolds, scaffolds incorporating plasmid DNA, and bolus 
injection of condensed DNA at both 8 and 15 weeks (Fig. 
1E–G and I–K). Strikingly, scaffolds encapsulating condensed
DNA still displayed extensive positive staining at both 8 and
15 weeks (Fig. 1H and L). Furthermore, staining was evenly
distributed at the outer surface and in the cross-section of 
scaffolds.
Cellular infiltration of host cells into the scaffolds under each
condition was also qualitatively and quantitatively determined.
The mass of each scaffold was determined, and there was an
increase in mass for all conditions over the time course from 2
to 15 weeks (Fig. 2A). The samples for all conditions at 15
weeks displayed a statistically significant increase in mass rel-
ative to 2- and 8-week time points for each condition (p  0.05).
However, there was no statistically significant difference in
mass between samples at each time point (p  0.05). The num-
ber of cells infiltrating the scaffolds also increased over time
for each condition (Fig. 2B). However, there were no statisti-
cally significant differences in cell number between experi-
mental conditions at each time point (p  0.05). These results
indicated continuous cell infiltration and tissue growth in this
delivery system. The cell types infiltrating the scaffolds, as
identified by FACS, included 30% endothelial cells, 18% 
lymphocytes, and 52% other cell types, which were mostly 
fibroblasts, as based on cell morphology observed in tissue 
sections.
The 15-week samples were subsequently paraffin embedded
and sectioned for histological examination. Sections were
stained with eosin only to allow ready contrast of positively 
-galactosidase-stained cells relative to negative cells. Sec-
tions taken from scaffolds with encapsulated condensed DNA
showed positive -galactosidase staining throughout the sec-
tion (Fig. 3A), corroborating the extensive staining observed on
gross examination of the scaffolds at that time point. No posi-
tive staining could be observed on sections from scaffolds in-
corporating plasmid DNA (Fig. 3B). To assess the transfection
efficiency of scaffolds incorporating condensed DNA, the sec-
tions were counterstained with hematoxylin (Fig. 3C). By com-
paring eosin-stained sections with sections stained with both
hematoxylin and eosin, it can be observed that approximately
55–60% of the total cells in the scaffolds displayed positive -
galactosidase staining. Higher magnification examination of
these cells demonstrated the expected, more intense nuclear
staining, confirming expression of the nucleus-targeting -
galactosidase plasmid (Fig. 3D).
The kinetics of gene expression were determined by quan-
tification of -galactosidase enzyme expression level at each
time point (Fig. 4). Scaffolds incorporating condensed -galac-
tosidase plasmid DNA exhibited a significant increase in gene
expression over time from 2 to 8 weeks, and this level was
maintained at the 15-week time point. The highest expression
level resulting from bolus delivery of condensed DNA was at
the 2-week time point, and this level rapidly decreased over
time. This result was in contrast to that of scaffolds encapsu-
lating condensed DNA, and highlighted the importance of sus-
tained delivery of DNA. The scaffolds incorporating uncon-
densed plasmid DNA also exhibited sustained gene expression
over the period of 2 to 15 weeks, but the level was lower than
that of scaffolds incorporating condensed DNA. Blank scaffolds
displayed background values of gene expression at all time
points. Scaffolds incorporating condensed -galactosidase plas-
mid resulted in a statistically significant increase in gene ex-
pression level, as compared with the other conditions, at each
time point. Furthermore, the expression level was at least one
order of magnitude higher than that of other conditions at the
2-week time point, and at least two orders of magnitude higher
than that of other conditions at the 8- and 15-week time points
(p  0.05, at all time points). The gene expression levels re-
sulting from scaffolds incorporating condensed DNA at both
the 8- and 15-week time points displayed a statistically signif-
icant increase relative to the 2-week time point (p  0.05), and
there was no statistically significant difference in expression
level between the 8- and 15-week time points for the scaffolds
incorporating condensed DNA (p  0.05).
DISCUSSION
In this study, we have demonstrated the feasibility of freeze-
dried PEI–DNA condensates incorporated within PLGA
sponges to efficiently transfect cells in vivo in a sustained man-
ner, compared with other control conditions to deliver plasmid
DNA, as shown by the gross appearance of explants. Scaffolds
encapsulating condensed DNA also demonstrated high trans-
fection efficiency and gene expression levels during the course
of the experimental period when compared with other condi-
tions. The lack of significant differences in mass and cell num-
ber between experimental conditions demonstrated comparable
tissue ingrowth under each condition.
A critical factor in the success of gene therapy is the extent
of cellular uptake and expression of DNA. The system described
here demonstrated at least 80% DNA retention efficiency within
scaffolds incorporating condensed DNA after the leaching step,
and sustained DNA delivery (Huang et al., 2003). The distinc-
tive contrast between the extent of gene expression resulting
from scaffolds incorporating condensed DNA, and both scaf-
folds incorporating uncondensed plasmid DNA and scaffolds
subjected to bolus injection of condensed DNA over 15 weeks
in this study, clearly indicates the importance of sustained de-
livery of condensed DNA for heightened and extended expres-
sion of transferred genes. The continuous infiltration of host
cells into the scaffolds, followed by the uptake of DNA, led to
long-term transfection. A high percentage (55–60%) of cells
within scaffolds incorporating condensed DNA at 15 weeks
demonstrated expression of DNA, further confirming this find-
ing. The rapid drop in -galactosidase expression levels at the
8-week time point for scaffolds implanted with a bolus injec-
tion of condensed DNA was expected, as a result of the short-
term availability of the plasmid to cells in this situation. The
stability of plasmid DNA incorporated by this method into
PLGA scaffolds has been previously confirmed (Shea et al.,
1999), suggesting that instability of plasmid DNA does not ex-
plain the decreased transfection over time with scaffolds en-
capsulating uncondensed plasmid DNA. These results high-
lighted the importance of sustained delivery for long-term gene
expression, as previously proposed (Shea et al., 1999). The abil-
ity to deliver DNA locally in a sustained manner has important
implications in tissue engineering, as it offers the possibility of
tightly controlling the extent and duration of expression of in-
ductive factors by host cells.
We have demonstrated that PLGA scaffolds capable of con-
trolled and sustained delivery of condensed DNA lead to en-
hanced and long-term transfection in vivo. The system developed
here combines the advantages of synthetic polymers for fabri-
cating scaffolds (e.g., reproducibility and biocompatibility) and
the enhanced transfection efficiency afforded by PEI. This sys-
tem will also potentially allow much lower doses of plasmid
DNA (e.g., on the order of micrograms) than are needed other-
wise (e.g., on the order of milligrams) (Bonadio et al., 1999) to
promote high levels of gene expression. Future issues that can
be addressed with this system include the ability of this system
to deliver DNA condensates into the surrounding tissues, as con-
trasted with transfecting cells that migrate into the scaffolds, and
identification of the cell types that are transfected within the scaf-
folds. In future studies, this system could be further modified to
increase cellular infiltration by modifying the polymer compo-
sition, and by incorporating growth factors that increase recruit-
ment of host cells into the scaffolds. This scaffold delivery sys-
tem will likely find great utility in a variety of tissue-engineering
applications (e.g., bone regeneration) because of the high level
and duration of expression achievable with this system.
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